Should a solid isoechoic thyroid nodule classified as TI‑RADS 3 that has grown to about 2 cm over ten years be evaluated with ultrasound‑guided fine‑needle aspiration and serum TSH and calcitonin testing?

Management of a 2 cm Solid Isoechoic TI-RADS 3 Thyroid Nodule with 10-Year Growth History

Yes, perform ultrasound-guided fine-needle aspiration immediately, along with serum TSH and calcitonin testing. The documented growth from smaller size to 2 cm over ten years represents significant progression that overrides the baseline TI-RADS 3 classification and mandates cytological evaluation. 1

Why Growth Trumps TI-RADS Classification

Documented growth of this magnitude is one of the strongest independent predictors of malignancy, far exceeding the significance of baseline ultrasound features. 1 The evidence demonstrates that:

• Any thyroid nodule enlarging by ≥3 mm in any dimension during surveillance warrants immediate cytological evaluation, regardless of initial TI-RADS score 1
• Growth to 2 cm represents an increase that is 5-6 times the threshold for clinical significance 1
• Only approximately 8% of papillary microcarcinomas enlarge by ≥3 mm over 10 years, making dramatic growth highly atypical for truly benign disease 1
• Rapid or progressive growth is an independent risk factor that outweighs baseline size and ultrasound appearance considerations 1

Size-Based Indications for FNA

Beyond the growth concern, the current 2 cm size alone justifies FNA:

• Any thyroid nodule ≥1 cm warrants FNA regardless of ultrasound features, according to multiple guideline societies 1
• The American College of Surgeons and NCCN specifically recommend evaluation of nodules larger than 2 cm even without suspicious features due to increased malignancy risk 1
• A nodule of 2-3 cm is considered a worrisome feature associated with 3-times greater risk of malignancy compared to smaller nodules 1

TI-RADS 3 Performance Data

While TI-RADS 3 nodules generally carry low malignancy risk, the evidence shows important nuances:

• In a large cohort, TI-RADS 3 nodules had an overall malignancy rate of 2.0% (8 of 384 nodules), with 75% being cytologically benign 2
• However, 17% of resected TI-RADS 3 nodules (8 of 48) were confirmed as carcinoma on final histology 2
• TI-RADS 3 classification showed a negative predictive value of 94.6% compared with Bethesda scoring, meaning approximately 5% still harbor malignancy 3
• Non-marked hypoechoic nodules (which includes isoechoic nodules) classified as TI-RADS 3 showed malignancy risk of 0.9% in one validation study 4

Essential Serum Testing

TSH Measurement

• Measure serum TSH to determine if the nodule is autonomously functioning 1
• Most thyroid cancers present with normal thyroid function, so TSH testing helps identify the minority of hyperfunctioning nodules that may not require FNA 1
• If TSH is suppressed, proceed to thyroid scintigraphy; if the nodule is "hot," FNA is not indicated and medical management may be preferred 1

Calcitonin Measurement

• Serum calcitonin should be measured as part of the diagnostic workup to screen for medullary thyroid carcinoma (MTC) 1
• Calcitonin testing has higher sensitivity for detecting MTC than FNA alone (detects 5-7% of thyroid cancers that FNA may miss) 1
• Even in nodules ≤1 cm without suspicious features, MTC can occur, and calcitonin measurement permits diagnosis of these cases 5
• FNA-calcitonin (calcitonin measured in FNA washout fluid) demonstrates 95-100% sensitivity for detecting MTC across various diagnostic thresholds 6

Recommended Diagnostic Algorithm

1. Order serum TSH and calcitonin immediately 1

2. Perform high-resolution ultrasound to reassess the nodule and document:

   • Current size in three dimensions
   • Echogenicity (confirm isoechoic vs. hypoechoic)
   • Presence or absence of microcalcifications
   • Margin characteristics (smooth vs. irregular)
   • Vascularity pattern (peripheral vs. central)
   • Cervical lymph node status in central and lateral compartments 1

3. Proceed with ultrasound-guided FNA regardless of TSH results (unless nodule is hyperfunctioning on scintigraphy):

   • Ultrasound guidance is superior to palpation-guided biopsy for accuracy 1
   • Request FNA-calcitonin measurement in the aspirate washout fluid 6
   • Ensure adequate sampling to minimize nondiagnostic results (occur in 5-20% of cases) 1

4. If FNA is nondiagnostic, repeat FNA under ultrasound guidance 1

5. If FNA shows follicular neoplasm (Bethesda IV) with normal TSH and "cold" appearance on scan, refer for surgical consultation 1

6. If FNA is suspicious (Bethesda V) or malignant (Bethesda VI), arrange surgical consultation within 2-4 weeks for total or near-total thyroidectomy with pre-operative lymph node assessment 1

Critical Pitfalls to Avoid

• Do not rely on TI-RADS classification alone when documented growth is present—growth is an independent high-risk feature 1
• Do not defer FNA based on isoechoic appearance—solid composition itself carries higher malignancy risk than cystic nodules 1
• Do not skip calcitonin testing—MTC can present in nodules without classic suspicious features and may be missed by cytology alone 5, 6
• Do not accept a single benign FNA result as definitive if clinical suspicion remains high—false-negative rates range from 5-33% depending on context 1
• Do not order radionuclide scanning in euthyroid patients—it does not add value for malignancy risk assessment 1

Age Considerations

If this patient is younger than 40 years, the indication for FNA is even stronger:

• Younger patients (<40 years) have independently higher risk of papillary microcarcinoma progression on multivariate analysis 1
• Younger individuals show greater progression rates in active-surveillance cohorts 1

Expected Outcomes and Next Steps

• If FNA yields Bethesda II (benign) cytology with normal calcitonin, surveillance with repeat ultrasound at 12-24 months is appropriate, as malignancy risk drops to 1-3% 1
• If FNA shows Bethesda III (AUS/FLUS) or IV (follicular neoplasm), consider molecular testing for BRAF, RAS, RET/PTC, and PAX8/PPARγ mutations to refine malignancy risk 1
• 97% of mutation-positive nodules are malignant, making molecular testing highly specific when positive 1
• For indeterminate cytology, core needle biopsy may be necessary if repeat FNA remains nondiagnostic 1